Ondansetron
- Generic Name
- Ondansetron
- Brand Names
- Zofran, Zuplenz
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N3O
- CAS Number
- 99614-02-5
- Unique Ingredient Identifier
- 4AF302ESOS
- Background
A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
...
- Indication
In the adult patient population:
i) orally administered ondansetron tablets and orally disintegrating tablets (ODT) are indicated for:
- the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and radiotherapy, and
...
- Associated Conditions
- Chemotherapy-Induced Nausea and Vomiting, Cholestatic pruritus, Post Operative Nausea and Vomiting (PONV), Radiation-Induced Nausea and Vomiting, Uremic Pruritus, Severe Hyperemesis gravidarum
- Associated Therapies
- -
Bioequivalence Study of Ondansetron Orally Disintegrating Tablets 8mg Under Fasting Conditions
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2012-02-09
- Lead Sponsor
- Ranbaxy Laboratories Limited
- Target Recruit Count
- 32
- Registration Number
- NCT01523093
- Locations
- 🇮🇳
Clinical Pharmacology Unit, Majeedia Hospital (2nd Floor), New Delhi, India
Bioequivalence Study of Ondansetron Orally Disintegrating Tablets 8mg Under Fed Conditions
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2012-02-09
- Lead Sponsor
- Ranbaxy Laboratories Limited
- Target Recruit Count
- 35
- Registration Number
- NCT01523119
- Locations
- 🇮🇳
Clinical Pharmacology Unit, Majeedia Hospital (2nd Floor), New Delhi, India
A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV)
- Conditions
- Interventions
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2012-10-02
- Lead Sponsor
- Accenture
- Target Recruit Count
- 131
- Registration Number
- NCT01507194
- Locations
- 🇺🇸
Visions Clinical Research, Boynton Beach, Florida, United States
🇺🇸CAP Anesthesia (St. Elizabeth's Medical Center), Boston, Massachusetts, United States
🇺🇸University of Pittsburg, Pittsburgh, Pennsylvania, United States
The Effect of Ondansetron During Intramuscular Ketamine Use in Children: A Trial in Emergency Department
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2012-01-20
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 266
- Registration Number
- NCT01477242
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting
- Conditions
- Interventions
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2013-12-03
- Lead Sponsor
- Sergio Bergese
- Target Recruit Count
- 122
- Registration Number
- NCT01474915
- Locations
- 🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide
- First Posted Date
- 2011-10-12
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- Katy Peters
- Target Recruit Count
- 136
- Registration Number
- NCT01450826
- Locations
- 🇺🇸
The Preston Robert Tisch Brain Tumor Center at Duke, Durham, North Carolina, United States
To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2011-10-10
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT01449188
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
- Conditions
- Interventions
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2014-08-07
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 502
- Registration Number
- NCT01442376
- Locations
- 🇺🇸
A. I. duPont Hospital for Children, Wilmington, Delaware, United States
🇺🇸Nemours Children's Clinic, Pensacola, Florida, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
Intravenous Ondansetron to Attenuate the Hypotensive, Bradycardic Response to Spinal Anesthesia in Healthy Parturients
- First Posted Date
- 2011-08-11
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 68
- Registration Number
- NCT01414777
- Locations
- 🇺🇸
University of Virginia Health System, Charlottesville, Virginia, United States
Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients
- Conditions
- Interventions
- First Posted Date
- 2011-07-18
- Last Posted Date
- 2014-07-30
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 670
- Registration Number
- NCT01395901
- Locations
- 🇺🇸
Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States
🇵🇱Department of Intensive Care and Anesthesiology, Olsztyn, Poland
🇺🇸Shoals Medical Research, LLC, Sheffield, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.